Marjorie Z. Imperial

机构：Gilead Sciences (United States) · ORCID：0000-0001-7434-3012

发表论文 25 篇 · 总被引 840 次 · h-index 10

代表论文

• A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis (2018 · Nature Medicine · 被引 387)
• Development of a Novel Maternal-Fetal Physiologically Based Pharmacokinetic Model I: Insights into Factors that Determine Fetal Drug Exposure through Simulations and Sensitivity Analyses (2017 · Drug Metabolism and Disposition · 被引 101)
• Tuberculosis Treatment Monitoring and Outcome Measures: New Interest and New Strategies (2022 · Clinical Microbiology Reviews · 被引 83)
• Proposed Linezolid Dosing Strategies to Minimize Adverse Events for Treatment of Extensively Drug-Resistant Tuberculosis (2021 · Clinical Infectious Diseases · 被引 62)
• Precision-Enhancing Risk Stratification Tools for Selecting Optimal Treatment Durations in Tuberculosis Clinical Trials (2021 · American Journal of Respiratory and Critical Care Medicine · 被引 56)
• Risk-stratified treatment for drug-susceptible pulmonary tuberculosis (2024 · Nature Communications · 被引 31)